FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592145214> ?p ?o ?g. }

• W2592145214 endingPage "24752" @default.
• W2592145214 startingPage "24741" @default.
• W2592145214 abstract "// Emi Harada 1, * , Satoshi Serada 1, * , Minoru Fujimoto 1 , Yusuke Takahashi 1 , Tsuyoshi Takahashi 2 , Hisashi Hara 2 , Rie Nakatsuka 2 , Takahito Sugase 2 , Takahiko Nishigaki 2 , Yurina Saito 2 , Kosuke Hiramatsu 1 , Satoshi Nojima 3 , Risa Mitsuo 1 , Tomoharu Ohkawara 1 , Eiichi Morii 3 , Masaki Mori 2 , Yuichiro Doki 2 , Yasufumi Kaneda 4 , Tetsuji Naka 1 1 Laboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan 2 Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan 3 Department of Pathology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan 4 Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan * These authors contributed equally to this work and share first authorship Correspondence to: Satoshi Serada, email: serada@nibiohn.go.jp Tetsuji Naka, email: tnaka@nibiohn.go.jp Keywords: esophageal squamous cell carcinoma, glypican-1 Received: August 17, 2016      Accepted: February 15, 2017      Published: March 01, 2017 ABSTRACT Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite the development of multimodal therapy. Expression of glypican-1 (GPC1) has been reported to be elevated in a subset of patients with ESCC and associated with chemoresistance. This study aimed to determine the association of GPC1 with ESCC growth and potential usefulness of the GPC1 targeted therapy by monoclonal antibody (mAb) in ESCC. Expression of GPC1 was higher in ESCC tumor tissues than in adjacent non-tumoral tissues and normal tissues. Knockdown of GPC1 decreased growth of ESCC cells and induced apoptosis via inhibition of EGFR, AKT and p44/42-MAPK signaling pathways in vitro . Anti-GPC1 mAb strongly inhibited tumor growth via antibody-dependent cellular cytotoxicity dependent and independent manner in GPC1-positive ESCC xenograft models. Anti-GPC1 mAb also inhibited tumor growth of GPC1 positive ESCC patients derived tumor xenograft models. Furthermore, anti-GPC1 mAb showed a significant tumor growth inhibition with decreased angiogenesis compared with IgG treated controls in ESCC xenografted mice. Treatment with anti-GPC1 mAb was not toxic in mice. Anti-GPC1 mAb may have a potent anti-tumor effect and represent a novel treatment option for patients with GPC1-positive ESCC." @default.
• W2592145214 created "2017-03-16" @default.
• W2592145214 creator A5003950298 @default.
• W2592145214 creator A5005164809 @default.
• W2592145214 creator A5006963101 @default.
• W2592145214 creator A5009314886 @default.
• W2592145214 creator A5013910008 @default.
• W2592145214 creator A5020771892 @default.
• W2592145214 creator A5026657616 @default.
• W2592145214 creator A5028284770 @default.
• W2592145214 creator A5041701717 @default.
• W2592145214 creator A5046856618 @default.
• W2592145214 creator A5049747685 @default.
• W2592145214 creator A5058902589 @default.
• W2592145214 creator A5065154218 @default.
• W2592145214 creator A5067647817 @default.
• W2592145214 creator A5070119035 @default.
• W2592145214 creator A5072947544 @default.
• W2592145214 creator A5080103837 @default.
• W2592145214 creator A5089579741 @default.
• W2592145214 creator A5091657288 @default.
• W2592145214 date "2017-03-01" @default.
• W2592145214 modified "2023-10-06" @default.
• W2592145214 title "Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma" @default.
• W2592145214 cites W152743852 @default.
• W2592145214 cites W1979728832 @default.
• W2592145214 cites W1982576397 @default.
• W2592145214 cites W1987556027 @default.
• W2592145214 cites W1995040137 @default.
• W2592145214 cites W2004898879 @default.
• W2592145214 cites W2014463647 @default.
• W2592145214 cites W2016568386 @default.
• W2592145214 cites W2020830322 @default.
• W2592145214 cites W2023575200 @default.
• W2592145214 cites W2041703901 @default.
• W2592145214 cites W2043752993 @default.
• W2592145214 cites W2061119693 @default.
• W2592145214 cites W2078843849 @default.
• W2592145214 cites W2080810010 @default.
• W2592145214 cites W2090138079 @default.
• W2592145214 cites W2107400825 @default.
• W2592145214 cites W2122687697 @default.
• W2592145214 cites W2131489568 @default.
• W2592145214 cites W2147144888 @default.
• W2592145214 cites W2159363679 @default.
• W2592145214 cites W2236189579 @default.
• W2592145214 cites W2318605753 @default.
• W2592145214 cites W2441351280 @default.
• W2592145214 cites W4210271223 @default.
• W2592145214 cites W4241399562 @default.
• W2592145214 cites W4252560545 @default.
• W2592145214 doi "https://doi.org/10.18632/oncotarget.15799" @default.
• W2592145214 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5421884" @default.
• W2592145214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28445969" @default.
• W2592145214 hasPublicationYear "2017" @default.
• W2592145214 type Work @default.
• W2592145214 sameAs 2592145214 @default.
• W2592145214 citedByCount "42" @default.
• W2592145214 countsByYear W25921452142017 @default.
• W2592145214 countsByYear W25921452142018 @default.
• W2592145214 countsByYear W25921452142019 @default.
• W2592145214 countsByYear W25921452142020 @default.
• W2592145214 countsByYear W25921452142021 @default.
• W2592145214 countsByYear W25921452142022 @default.
• W2592145214 countsByYear W25921452142023 @default.
• W2592145214 crossrefType "journal-article" @default.
• W2592145214 hasAuthorship W2592145214A5003950298 @default.
• W2592145214 hasAuthorship W2592145214A5005164809 @default.
• W2592145214 hasAuthorship W2592145214A5006963101 @default.
• W2592145214 hasAuthorship W2592145214A5009314886 @default.
• W2592145214 hasAuthorship W2592145214A5013910008 @default.
• W2592145214 hasAuthorship W2592145214A5020771892 @default.
• W2592145214 hasAuthorship W2592145214A5026657616 @default.
• W2592145214 hasAuthorship W2592145214A5028284770 @default.
• W2592145214 hasAuthorship W2592145214A5041701717 @default.
• W2592145214 hasAuthorship W2592145214A5046856618 @default.
• W2592145214 hasAuthorship W2592145214A5049747685 @default.
• W2592145214 hasAuthorship W2592145214A5058902589 @default.
• W2592145214 hasAuthorship W2592145214A5065154218 @default.
• W2592145214 hasAuthorship W2592145214A5067647817 @default.
• W2592145214 hasAuthorship W2592145214A5070119035 @default.
• W2592145214 hasAuthorship W2592145214A5072947544 @default.
• W2592145214 hasAuthorship W2592145214A5080103837 @default.
• W2592145214 hasAuthorship W2592145214A5089579741 @default.
• W2592145214 hasAuthorship W2592145214A5091657288 @default.
• W2592145214 hasBestOaLocation W25921452141 @default.
• W2592145214 hasConcept C121608353 @default.
• W2592145214 hasConcept C126322002 @default.
• W2592145214 hasConcept C143998085 @default.
• W2592145214 hasConcept C2781230642 @default.
• W2592145214 hasConcept C2994415158 @default.
• W2592145214 hasConcept C502942594 @default.
• W2592145214 hasConcept C71924100 @default.
• W2592145214 hasConceptScore W2592145214C121608353 @default.
• W2592145214 hasConceptScore W2592145214C126322002 @default.
• W2592145214 hasConceptScore W2592145214C143998085 @default.
• W2592145214 hasConceptScore W2592145214C2781230642 @default.
• W2592145214 hasConceptScore W2592145214C2994415158 @default.

• next